Paris-based Cure51 raises €15 million to develop first-in-class treatments from exceptional cancer survivors
Summary
Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, announced that it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. The funding received will enable Cure51 to build a unique cohort, exploring the molecular processes by which certain cancer patients survive for very extended periods of time despite having highly aggressive forms of the disease. “Cure51’s strong clinical network and ambitious team make this an investment we’re thrilled to support.” “Modern AI models require world class datasets to uncover novel biology and discover transformative medicines, and this is what Cure51 is uniquely creating for cancer patients,” noted Joanna Soroka, PhD, Principal at Hitachi Ventures GmbH. “With this support, we are on our way to unlocking survival mechanisms and ultimately, saving countless lives,” added Simon Istolainen, Cure51 Co-founder and Chief Strategy and Scientific Network Officer. Using its discovery platform powered by computational modeling, Cure51 aims to understand the biological mechanisms responsible for this exceptional survival by identifying and validating targets that can act on these interactions, leading to first in class treatments.